CO2022001195A2 - Anticuerpos dirigidos contra dll3 y usos de los mismos - Google Patents

Anticuerpos dirigidos contra dll3 y usos de los mismos

Info

Publication number
CO2022001195A2
CO2022001195A2 CONC2022/0001195A CO2022001195A CO2022001195A2 CO 2022001195 A2 CO2022001195 A2 CO 2022001195A2 CO 2022001195 A CO2022001195 A CO 2022001195A CO 2022001195 A2 CO2022001195 A2 CO 2022001195A2
Authority
CO
Colombia
Prior art keywords
dll3
directed against
antibodies directed
antibodies
against dll3
Prior art date
Application number
CONC2022/0001195A
Other languages
English (en)
Inventor
John T Poirier
Charles Rudin
Jason Lewis
Abdul Khan
David Andrew
Xinlei Chen
Ivo Lorenz
Original Assignee
Memorial Sloan Kettering Cancer Center
Tri Inst Therapeutics Discovery Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Tri Inst Therapeutics Discovery Inst filed Critical Memorial Sloan Kettering Cancer Center
Publication of CO2022001195A2 publication Critical patent/CO2022001195A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere generalmente a composiciones relacionadas con inmunoglobulinas (por ejemplo, anticuerpos o fragmentos de unión a antígeno de los mismos) que se pueden unir a la proteína 3 de tipo delta (DLL3). Los anticuerpos de la presente tecnología son útiles en los métodos para detectar y tratar un cáncer asociado a DLL3 en un sujeto que lo necesita.
CONC2022/0001195A 2019-07-11 2022-02-04 Anticuerpos dirigidos contra dll3 y usos de los mismos CO2022001195A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2022001195A2 true CO2022001195A2 (es) 2022-03-08

Family

ID=74115317

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001195A CO2022001195A2 (es) 2019-07-11 2022-02-04 Anticuerpos dirigidos contra dll3 y usos de los mismos

Country Status (12)

Country Link
US (1) US20220348648A1 (es)
EP (1) EP3997127A4 (es)
JP (1) JP2022540611A (es)
KR (1) KR20220034167A (es)
CN (1) CN114341182A (es)
AU (1) AU2020310894A1 (es)
BR (1) BR112022000216A2 (es)
CA (1) CA3146566A1 (es)
CO (1) CO2022001195A2 (es)
IL (1) IL289585A (es)
MX (1) MX2022000325A (es)
WO (1) WO2021007371A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (es) * 2014-05-30 2018-04-14
TW202237135A (zh) * 2021-01-13 2022-10-01 紀念斯隆凱特琳癌症中心 抗體-吡咯并苯并二氮呯衍生物結合物
TW202245844A (zh) * 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
TW202302650A (zh) * 2021-05-08 2023-01-16 大陸商上海齊魯製藥研究中心有限公司 針對dll3的結合分子及其應用
WO2023034555A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003282780A1 (en) * 2003-08-08 2005-03-07 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
WO2008066691A2 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US9150648B2 (en) * 2012-01-31 2015-10-06 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
SG11201405131XA (en) * 2012-02-24 2014-10-30 Stemcentrx Inc Dll3 modulators and methods of use
CR20160437A (es) * 2014-02-21 2017-02-20 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma
SI3221356T1 (sl) * 2014-11-20 2021-01-29 F. Hoffmann-La Roche Ag Bispecifične molekule, ki vežejo antigene in aktivirajo celice T, proti FOLR1 in CD3

Also Published As

Publication number Publication date
BR112022000216A2 (pt) 2022-05-17
CA3146566A1 (en) 2021-01-14
KR20220034167A (ko) 2022-03-17
MX2022000325A (es) 2022-03-25
CN114341182A (zh) 2022-04-12
JP2022540611A (ja) 2022-09-16
EP3997127A4 (en) 2023-08-23
US20220348648A1 (en) 2022-11-03
WO2021007371A1 (en) 2021-01-14
AU2020310894A1 (en) 2022-02-03
EP3997127A1 (en) 2022-05-18
IL289585A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CO2022001195A2 (es) Anticuerpos dirigidos contra dll3 y usos de los mismos
CL2019002855A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno.
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112019000431A2 (pt) anticorpos contra tim3 e usos dos mesmos
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112018011100A2 (pt) anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição.
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
WO2018031490A3 (en) Anti-ox40 binding proteins
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos